Actaea Racemosa Whole Apis Mellifera Graphite Oyst
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Actaea Racemosa Whole Apis Mellifera Graphite Oyst
- Multi-Ingredient Homeopathic Preparation: No TxGNN Prediction Available
Multi-Ingredient Homeopathic Preparation: No TxGNN Prediction Available
One-Sentence Summary
This evidence pack describes a complex 8-component homeopathic combination (including Black Cohosh, Honeybee, Pulsatilla, and Graphite) with no established regulatory record in Taiwan or the United States. The TxGNN model returned no predicted new indications for this combination, most likely because none of the individual components could be matched to a DrugBank ID in the knowledge graph. Without a valid drug node in the TxGNN graph, repurposing scoring cannot be performed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (Model prediction only — no predictions generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
This product is a homeopathic multi-ingredient preparation. Its components are:
| Component | Homeopathic Origin | Standard Database Match |
|---|---|---|
| Actaea Racemosa Whole | Black Cohosh (whole plant) | Partial (Black Cohosh extract has DrugBank entry; crude whole-plant form typically does not) |
| Apis Mellifera | Honeybee (homeopathic preparation) | Not in DrugBank |
| Graphite | Graphites (homeopathic mineral) | Not in DrugBank |
| Oyster Shell Calcium Carbonate, Crude | Calcarea Carbonica (homeopathic) | Not in DrugBank |
| Pulsatilla Pratensis Whole | Pasqueflower (homeopathic) | Not in DrugBank |
| Rhododendron Ferrugineum Flower | Alpine Rose (homeopathic) | Not in DrugBank |
| Samarium | Rare earth element (homeopathic dilution) | Not in DrugBank |
| Sodium Chloride | Natrum Muriaticum (homeopathic) | Not in DrugBank as homeopathic preparation |
The TxGNN knowledge graph is anchored to DrugBank IDs. Because no DrugBank ID could be resolved for this multi-ingredient combination (query returned 0 matches despite 1 result logged — likely a partial or unresolvable hit), the drug node does not exist in the graph and repurposing scoring was not executed.
Mechanistic analysis is also not possible because no MOA data is available and homeopathic preparations are not represented in pharmacological pathway databases.
Clinical Trial Evidence
Currently no related clinical trials registered for this multi-ingredient combination as a repurposing candidate. Individual components (e.g., Black Cohosh / Actaea Racemosa extract) have separate clinical trial records for menopausal symptoms, but these are for standardized pharmaceutical-grade extracts, not this crude homeopathic preparation.
Literature Evidence
Currently no related literature available for TxGNN-predicted repurposing of this combination. If the target indication were identified, a component-level literature search (e.g., Black Cohosh for specific indications) could be performed as a proxy.
US Market Information
This product has no recorded NDA, ANDA, or OTC monograph approval in the United States database queried. Homeopathic products in the US may be marketed under FDA enforcement discretion policies (CPG 400.400 / 2019 Guidance), but no formal approval exists for this specific formulation.
Safety Considerations
Please refer to the package insert for safety information. No structured safety data (warnings, contraindications, or drug interactions) could be retrieved for this combination. Individual component notes for reference:
- Actaea Racemosa (Black Cohosh): Associated with rare hepatotoxicity reports; contraindicated in pregnancy.
- Pulsatilla: May have uterotonic effects in concentrated doses.
- Other components at homeopathic dilutions are generally considered inert pharmacologically, though individual sensitivities may vary.
Conclusion and Next Steps
Decision: Hold
Rationale: This product cannot proceed through the TxGNN repurposing pipeline because no valid DrugBank node exists for it, resulting in zero predicted indications. Additionally, the product has no regulatory approval, no identified original indication, and no retrievable safety data — making evidence-based repurposing analysis impossible at this stage.
To proceed, the following is needed:
- Clarify the target drug: Determine if the intended subject is a specific active component within this combination (e.g., Actaea Racemosa / Black Cohosh extract), and resubmit with the correct INN for that component
- DrugBank ID resolution: If the combination is to be evaluated as a whole, a DrugBank ID or equivalent pharmacological identifier must be established
- Original indication definition: Document what clinical purpose this preparation was formulated for, so downstream indication-to-indication comparison is meaningful
- Regulatory status clarification: Verify whether any component has independent NDA/ANDA approval that could serve as the regulatory anchor
- MOA documentation: Retrieve mechanism of action data (even at component level) to enable mechanistic plausibility scoring
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.